CTOs on the Move

OHS COMPCARE

www.ohs.com

 
OHS COMPCARE is a Mercer Island, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.ohs.com
  • 7525 SE 24th St
    Mercer Island, WA USA 98040
  • Phone: 800.829.2925

Executives

Name Title Contact Details

Similar Companies

Cook County Health and Hospitals System

The Cook County Health and Hospitals Systems mission is to deliver integrated health services with dignity and respect regardless of a patients ability to pay; foster partnerships with other health providers and communities to enhance the health of the public; and advocate for policies that promote the physical, mental and social well being of the people of Cook County. CCHHS is comprised of two hospitals, John H. Stroger, Jr. Hospital and Provident Hospital, a robust network of more than a dozen community health centers, the Ruth M. Rothstein CORE Center, the Cook County Department of Public Health, Cermak Health Services, which provides health care to individuals at the Cook County Jail and the Juvenile Temporary Detention Center, and CountyCare, a Medicaid managed care health plan. The system cares for more than 300,000 patients each year and its physicians are experts in their fields, committed to providing their patients with comprehensive, compassionate and cutting-edge care. Today, CCHHS is transforming the provision of health care in Cook County by promoting community-based primary and preventive care, growing an innovative, collaborative health plan and enhancing the patient experience.

RCM of Washington

RCM of Washington is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nexera Consulting

Nexera Consulting is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MSI

MSI Methylation Sciences Inc. (“MSI”) is a clinical-stage pharmaceutical company focused on developing new products based on molecules which have clinical proof of concept but which have yet to be exploited in the major pharmaceutical markets. MSI`s focus is in the CNS space where clinical proof of concept is key to reducing the drug development risk. Our lead product candidate, Strada™, is based upon Ademetionine, a naturally occurring molecule produced throughout the body, where it plays a vital role in the one-carbon cycle. Our disease indication is Major Depressive Disorder (MDD).

Sarah Cannon Research Institute

SCRI, an industry leader in clinical trials, is dedicated to advancing therapies for patients through clinical research.